Biogen (HAM:IDP) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:IDP Biogen Inc HAM:IDP
74 GF Score
Price €176.38
GF Value €161.82
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Biogen SpecialCharges?

Special Charges only applies to banks.

HAM:IDP
74GF Score
Biogen Inc HAM:IDP
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biogen (HAM:IDP) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of €176.38 is trading 9% above its estimated GF Value™ of €161.82. GuruFocus considers Biogen to be Fairly Valued.

Key valuation signals for HAM:IDP:

  • SpecialCharges:
  • GF Value™: €161.82 vs. price of €176.38 (9% above fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the HAM:IDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
74GF Score

Get the complete analysis for HAM:IDP

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€176.38
Price
€161.82
GF Value